CN113508133A - 人源化抗Aβ单克隆抗体及其应用 - Google Patents

人源化抗Aβ单克隆抗体及其应用 Download PDF

Info

Publication number
CN113508133A
CN113508133A CN202080011908.6A CN202080011908A CN113508133A CN 113508133 A CN113508133 A CN 113508133A CN 202080011908 A CN202080011908 A CN 202080011908A CN 113508133 A CN113508133 A CN 113508133A
Authority
CN
China
Prior art keywords
amino acid
monoclonal antibody
acid sequence
seq
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080011908.6A
Other languages
English (en)
Other versions
CN113508133B (zh
Inventor
冯晓
肖亮
金磊
孙大为
梁阳秋
刘爽
王涛
陈宇珩
李正一
刘淑芹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changchun Genescience Pharmaceutical Co Ltd
Original Assignee
Changchun Genescience Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changchun Genescience Pharmaceutical Co Ltd filed Critical Changchun Genescience Pharmaceutical Co Ltd
Publication of CN113508133A publication Critical patent/CN113508133A/zh
Application granted granted Critical
Publication of CN113508133B publication Critical patent/CN113508133B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

本发明涉及抗体药物技术领域，尤其涉及人源化抗Aβ单克隆抗体及其应用。本发明提供的人源化抗Aβ单克隆抗体能够促进巨噬细胞对Aβ的吞噬，保护神经细胞免受Aβ的毒性，有一定的改善阿尔茨海默痴呆模型小鼠认知学习记忆能力的作用，可用于治疗和诊断淀粉样变性相关的疾病和病症，如阿尔茨海默病。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202080011908.6A 2019-02-01 2020-01-17 人源化抗Aβ单克隆抗体及其应用 Active CN113508133B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019101048689 2019-02-01
CN201910104868.9A CN111518207B (zh) 2019-02-01 2019-02-01 人源化抗Aβ单克隆抗体及其应用
PCT/CN2020/072626 WO2020156220A1 (zh) 2019-02-01 2020-01-17 人源化抗Aβ单克隆抗体及其应用

Publications (2)

Publication Number Publication Date
CN113508133A true CN113508133A (zh) 2021-10-15
CN113508133B CN113508133B (zh) 2023-04-07

Family

ID=71840797

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910104868.9A Active CN111518207B (zh) 2019-02-01 2019-02-01 人源化抗Aβ单克隆抗体及其应用
CN202080011908.6A Active CN113508133B (zh) 2019-02-01 2020-01-17 人源化抗Aβ单克隆抗体及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910104868.9A Active CN111518207B (zh) 2019-02-01 2019-02-01 人源化抗Aβ单克隆抗体及其应用

Country Status (2)

Country Link
CN (2) CN111518207B (zh)
WO (1) WO2020156220A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591918A (zh) * 2022-05-07 2022-06-07 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518207B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN114591917B (zh) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101531717A (zh) * 2009-04-22 2009-09-16 北京交通大学 抗阿尔茨海默病单克隆抗体及其应用
CN101622275A (zh) * 2007-01-05 2010-01-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
CN105461808A (zh) * 2015-12-24 2016-04-06 长春金赛药业有限责任公司 单克隆抗体及其应用
CN106084052A (zh) * 2016-06-17 2016-11-09 长春金赛药业有限责任公司 抗cd47单克隆抗体及其应用
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CN106928354A (zh) * 2017-04-25 2017-07-07 长春金赛药业有限责任公司 抗IL‑1β单克隆抗体及其应用
CN111518206A (zh) * 2019-02-01 2020-08-11 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN111518207B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09178743A (ja) * 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
CN107561264B (zh) * 2017-09-05 2020-03-27 齐鲁工业大学 基于图像处理的β淀粉样斑块识别和测量方法
CN108250296B (zh) * 2018-01-17 2020-07-07 长春金赛药业有限责任公司 全人源抗人pd-l1单克隆抗体及其应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101622275A (zh) * 2007-01-05 2010-01-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
CN101531717A (zh) * 2009-04-22 2009-09-16 北京交通大学 抗阿尔茨海默病单克隆抗体及其应用
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CN105461808A (zh) * 2015-12-24 2016-04-06 长春金赛药业有限责任公司 单克隆抗体及其应用
CN106084052A (zh) * 2016-06-17 2016-11-09 长春金赛药业有限责任公司 抗cd47单克隆抗体及其应用
CN106928354A (zh) * 2017-04-25 2017-07-07 长春金赛药业有限责任公司 抗IL‑1β单克隆抗体及其应用
CN111518206A (zh) * 2019-02-01 2020-08-11 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN111518207B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER H.VAN DYCK: "Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise", 《BIOL PSYCHIATRY》 *
陈泉金等: "抗β单克隆抗体对痴呆模型小鼠学习记忆功能的影响", 《新疆医科大学学报》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591918A (zh) * 2022-05-07 2022-06-07 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途

Also Published As

Publication number Publication date
CN111518207A (zh) 2020-08-11
WO2020156220A1 (zh) 2020-08-06
CN113508133B (zh) 2023-04-07
CN111518207B (zh) 2022-03-29

Similar Documents

Publication Publication Date Title
CN113508132B (zh) 人源化抗Aβ单克隆抗体及其应用
RU2760334C2 (ru) Моноклональные антитела к альфа-синуклеину для предотвращения агрегации тау-белка
WO2018095428A1 (zh) Cd47抗体、其抗原结合片段及其医药用途
CN113508133B (zh) 人源化抗Aβ单克隆抗体及其应用
TW202017945A (zh) 抗ｃｄ７３抗體、其抗原結合片段及應用
CN111744013A (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
WO2021098822A1 (zh) 一种双特异性抗体
CN113508131B (zh) 人源化抗Aβ单克隆抗体及其应用
TW202140547A (zh) 抗ａｎｇｐｔｌ３抗體及其應用
CN112513088A (zh) 抗ox40抗体、其抗原结合片段及其医药用途
CN113840836B (zh) 抗结缔组织生长因子抗体及其应用
WO2020015637A1 (zh) 抗Abeta抗体、其抗原结合片段及应用
RU2783528C1 (ru) ГУМАНИЗИРОВАННОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Aβ и ЕГО ПРИМЕНЕНИЕ
TWI843799B (zh) 抗pd-1抗體、其抗原結合片段及醫藥用途
CN117946265A (zh) 抗cx3cl1抗体及其应用
CN116606373A (zh) 新型冠状病毒中和抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant